文献速递脊柱关节炎

英国中轴型脊柱关节炎患者中粒细胞-巨噬细胞集落刺激因子中和治疗(NAMASTE):一项随机、双盲、安慰剂对照的2期试验

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Rheumatol · 2024-06-25

NAMASTE试验在英国9家医院纳入42例中重度活动性中轴型脊柱关节炎患者,按6:1随机接受那米鲁单抗150 mg皮下注射或安慰剂,主要终点第12周ASAS20应答率未达到。那米鲁单抗组ASAS20应答比例低于安慰剂组(14/36 vs 3/6,估计组间差异6.8%),贝叶斯后验概率η为0.72。治疗总体耐受性良好。

要点

  • 那米鲁单抗组第12周ASAS20应答比例低于安慰剂组(14/36 vs 3/6),主要终点未达到。
  • 贝叶斯后验概率η为0.72,原文指出>0.927提示高临床意义。
  • 那米鲁单抗组与安慰剂组任何治疗中出现的不良事件发生率相似(31 vs 5)。

核心结论

  • 那米鲁单抗与安慰剂相比在活动性中轴型脊柱关节炎患者中未显示疗效,但治疗总体耐受性良好。

研究设计与样本

  • 这是一项在英国9家医院开展的概念验证、随机、双盲、安慰剂对照、2期贝叶斯(NAMASTE)试验。
  • 纳入18-75岁符合ASAS标准及ASAS定义的MRI标准、BASDAI定义的活动性疾病、且对既往抗TNF药物治疗应答不足或不耐受的中轴型脊柱关节炎患者。
  • 42例患者按6:1随机分配至那米鲁单抗150 mg皮下注射组(n=36)或安慰剂组(n=6),在第0、2、6、10周给药。
  • 主要终点为全分析集(所有随机分配参与者)第12周达到ASAS20临床应答的参与者比例。

主要发现

  • 2018年9月6日至2019年7月25日,60例中重度活动性中轴型脊柱关节炎患者接受资格评估,42例被随机分配。
  • 参与者平均年龄39.5岁(SD 13.3),17例女性、25例男性,39例白人,7例既往接受过抗TNF治疗。
  • 第12周那米鲁单抗组ASAS20临床应答比例为14/36,低于安慰剂组的3/6,估计组间差异为6.8%。
  • 贝叶斯后验概率η为0.72(原文指出>0.927提示高临床意义)。
  • 那米鲁单抗组任何治疗中出现的不良事件发生率为31,安慰剂组为5。

关键数值与推荐

  • 主要终点未达到:第12周ASAS20应答那米鲁单抗组14/36 vs 安慰剂组3/6,估计组间差异6.8%。
  • 贝叶斯后验概率η=0.72,原文阈值>0.927提示高临床意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibody that potently neutralises human GM-CSF. We aimed to assess the efficacy of namilumab in participants with moderate-to-severe active axial spondyloarthritis. METHODS: This proof-of-concept, randomised, double-blind, placebo-controlled, phase 2, Bayesian (NAMASTE) trial was done at nine hospitals in the UK. Participants aged 18-75 years with axial spondyloarthritis, meeting the Assessment in SpondyloArthritis international Society (ASAS) criteria and the ASAS-defined MRI criteria, with active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), were eligible. Those who had inadequately responded or had intolerance to previous treatment with an anti-TNF agent were included. Participants were randomly assigned (6:1) to receive subcutaneous namilumab 150 mg or placebo at weeks 0, 2, 6, and 10. Participants, site staff (except pharmacy staff), and central study staff were masked to treatment assignment. The primary endpoint was the proportion of participants who had an ASAS ≥20% improvement (ASAS20) clinical response at week 12 in the full analysis set (all randomly assigned participants). This trial is registered with ClinicalTrials.gov (NCT03622658). FINDINGS: From Sept 6, 2018, to July 25, 2019, 60 patients with moderate-to-severe active axial spondyloarthritis were assessed for eligibility and 42 were randomly assigned to receive namilumab (n=36) or placebo (n=six). The mean age of participants was 39·5 years (SD 13·3), 17 were women, 25 were men, 39 were White, and seven had previously received anti-TNF therapy. The primary endpoint was not met. At week 12, the proportion of patients who had an ASAS20 clinical response was lower in the namilumab group (14 of 36) than in the placebo group (three of six; estimated between-group difference 6·8%). The Bayesian posterior probability η was 0·72 (>0·927 suggests high clinical significance). The rates of any treatment-emergent adverse events in the namilumab group were similar to those in the placebo group (31 vs five). INTERPRETATION: Namilumab did not show efficacy compared with placebo in patients with active axial spondyloarthritis, but the treatment was generally well tolerated. FUNDING: Izana Bioscience, NIHR Oxford Biomedical Research Centre (BRC), NIHR Birmingham BRC, and Clinical Research Facility.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Worth C, Al-Mossawi MH, Macdonald J, et al. Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2024. PMID: 38942047. doi:10.1016/S2665-9913(24)00099-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。